Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. (0LB2.L) Financial Performance & Income Statement Overview
Explore the financials of Supernus Pharmaceuticals, Inc. (0LB2.L), including yearly and quarterly data on income, cash flow, and balance sheets.
Supernus Pharmaceuticals, Inc. (0LB2.L) Income Statement & Financial Overview
Access detailed annual and quarterly income data for Supernus Pharmaceuticals, Inc. 0LB2.L financial performance.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $149.82M | $174.16M | $175.69M | $168.32M |
| Cost of Revenue | $15.76M | $26.10M | $37.67M | $38.62M |
| Gross Profit | $134.06M | $129.22M | $138.02M | $129.70M |
| Gross Profit Ratio | $0.89 | $0.74 | $0.79 | $0.77 |
| R&D Expenses | $26.93M | $28.05M | $29.04M | $25.58M |
| SG&A Expenses | $89.94M | $79.41M | $69.75M | $85.90M |
| Operating Expenses | $144.32M | $126.66M | $117.26M | $111.49M |
| Total Costs & Expenses | $160.08M | $152.75M | $134.84M | $150.11M |
| Interest Income | $4.42M | $4.98M | $4.10M | $3.73M |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $20.38M | $18.84M | $20.10M | $20.71M |
| EBITDA | $17.79M | $45.23M | $65.03M | $38.92M |
| EBITDA Ratio | $0.12 | $0.26 | $0.37 | $0.23 |
| Operating Income | -$10.26M | $21.41M | $40.84M | $18.21M |
| Operating Income Ratio | -$0.07 | $0.12 | $0.23 | $0.11 |
| Other Income/Expenses (Net) | $4.42M | $4.98M | $4.10M | $3.73M |
| Income Before Tax | -$5.83M | $26.38M | $44.94M | $26.30M |
| Income Before Tax Ratio | -$0.04 | $0.15 | $0.26 | $0.16 |
| Income Tax Expense | $6.00M | $11.05M | $6.45M | $6.39M |
| Net Income | -$11.83M | $15.33M | $38.50M | $19.92M |
| Net Income Ratio | -$0.08 | $0.09 | $0.22 | $0.12 |
| EPS | -$0.21 | $0.28 | $0.70 | $0.36 |
| Diluted EPS | -$0.21 | $0.27 | $0.69 | $0.36 |
| Weighted Avg Shares Outstanding | $55.86M | $55.47M | $55.15M | $54.98M |
| Weighted Avg Shares Outstanding (Diluted) | $55.86M | $56.46M | $56.02M | $55.72M |
The company's financials show resilient growth, with revenue advancing from $168.32M in Q2 2024 to $149.82M in Q1 2025. Gross profit remained healthy with margins at 89% in Q1 2025 compared to 77% in Q2 2024. Operating income hit -$10.26M last quarter, sustaining a consistent -7% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $17.79M. Net income dropped to -$11.83M, while earnings per share reached -$0.21. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan